Monoclonal antibodies

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 1, 2001, Pages 64-70

  La Pine, Timothy R ^a   Hill, Harry R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR; CYTOKINE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 1 ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; STREPTOCOCCUS AGALACTIAE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; PATHOGENESIS; SEPSIS; SEPTIC SHOCK;

EID: 0035136667     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.19241     Document Type: Article

References (60)

1. Immunomodulating agents
2. Return to the past: The case for antibody-based therapies
3. Serum therapy revisited: Animal models of infection and development of passive antibody therapy
4. The therapy of (horse) serum reactions, general rules in the administration of therapeutic serums
5. Continuous cultures of fused cells secreting antibody of predefined specificity
6. Therapeutic monoclonal antibodies
7. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
8. Genetically engineered antibodies: Progress and prospects
9. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
10. 54-wk clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab in patients with active RA despite methotrexate
11. Infliximab for the treatment of fistulas in patients with Crohn's disease
12. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD 20 monoclonal antibody and CHOP chemotherapy
13. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
14. The potential use of monoclonal antibodies as therapeutic modallties in neonatal infection in IVIG therapy today
15. A serologic differentiation of specific types of bovine hemolytic streptococci (group B)
16. Two serological types of group B hemolytic streptococci with related, but not identical, type-specific substances
17. Type-specific polysaccharide antigens of group B streptococci
18. Multiple mouse protective antibodies directed against group B streptococci
19. Blood-transfusion in group-B streptococcal sepsis
20. Intravenous immunoglobulin in the treatment of neonatal sepsis: Therapeutic strategies and laboratory studies
21. Intravenous IgG in combination with other modalities in the treatment of neonatal infection
22. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus
23. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci
24. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease
25. An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin
26. Monoclonal antibody preparatious for immunotherapy of experimental GBS infection
27. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease
28. Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci
29. Human monoclonal antibodies to group B streptococcus
30. Potential for intravenous gamma-globulin use in neonatal gram-negative infection: An overview
31. Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis
32. Influence of growth temperature of Escherichia coli on K1 capsular antigen production and resistance to opsonization
33. Opsonization of various (K) E. coli by the alternative complement pathway
34. Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen
35. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B Streptococcus and Escherichia coli K1
36. Monoclonal antibody 2-2-B kills K1-positive Escherichia coli in conjunction with cord blood neutrophils and scra, but not with spinal fluid
37. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K 1 infection
38. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections
39. Monoclonal antibody enhances survival in neonatal models of lethal staphylococcal sepsis
40. Molecular and functional characteristics of a protective human monoclonal antibody to scrotype 8 Streptococcus pneumoniae capsular polysaccharide
41. Why immunomodulatory therapies have not worked in sepsis
42. Treatment of sepsis: Past and future avenues
43. Clinical immunology and infectious diseases
44. Treatment of gram-negative bactremia and shock with human antiserum to a mutant Escherichia coli
45. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid
46. A controlled trial of E5 routine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
47. Treatment of gram-negative bactremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial
48. Introduction of new technology into critical care practice. A history of HA-1A human monoclonal antibody against endotoxin
49. Endotoxin-core antibodies: Time for a reappraisal?
50. Inhibitors of complement and neutrophils: A critical evaluation of their role in the treatment of sepsis
51. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury
52. Role of tumor necrosis factor and interferon gamma in endotoxin-induced E-selectin expression
53. Anti L-selectin antibody treatment of hemorrhagic-traumatic shock in baboons
54. PAF and CD18 mediate neutrophil infiltration in upper gastrointestinal tract during intra-abdominal sepsis
55. Immunomodifiers applicable to the prevention and management of infectious diseases in children
56. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia
57. Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits
58. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
59. Experimental therapies for sepsis directed against tumor necrosis factor
60. Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci